Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

LGND stock hub

Ligand Pharmaceuticals Incorporated has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LGNDis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

4.4B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

LGND

In the news

Latest news · LGND

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E43.2

P25 12.3P50 18.4P75 33.1

Trailing P/E29.5

P25 14.9P50 23.2P75 38.5

ROE17.1

P25 -105.6P50 -46.5P75 -3.1

ROIC12

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LGND market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

263

Groups with data

Currency

USD

Showing 263 of 263 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000886163
Company name	Ligand Pharmaceuticals Incorporated
Country	United States
Country code	US
Cusip	53220K504
Employees	47
Employees Change	-21%
Employees Change Percent	-30.88
Enterprise value	$4.1B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	1992-11-18
Isin	US53220K5048
Last refreshed	2026-05-10
Market cap	$4.4B
Market cap category	Mid-Cap
Price	$221
Price currency	USD
Rev Per Employee	5,839,914.89x
Sector	Healthcare
Sic	2834
Symbol	LGND
Website	https://www.ligand.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.46%
EV Earnings	26.76x
EV Sales Forward	19.4x
EV/EBIT	40.6x
EV/EBITDA	30.57x
EV/FCF	33.41x
EV/Sales	14.97x
FCF yield	2.77%
Forward P/E	43.16x
P/B ratio	4.45x
P/E ratio	29.52x
P/S ratio	16.17x
PE Ratio10 Y	64.63x
PE Ratio3 Y	38.83x
PE Ratio5 Y	43.35x
PEG ratio	2.29x
PS Forward	20.95x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	36.88%
EBITDA Margin	48.98%
FCF margin	44.82%
Gross margin	83.16%
Gross Profit	$228.3M
Gross Profit Growth	121.81%
Gross Profit Growth3 Y	24.49%
Gross Profit Growth5 Y	15.9%
Net Income	$153.6M
Net Income Growth Quarters	4%
Net Income Growth Years	1%
Net Income Growth3 Y	85.72%
Net Income Growth5 Y	31.37%
Pretax Margin	67.36%
Profit Margin	55.95%
Profit Per Employee	$3.3M
Profitable Years	1
ROA	5.19
Roa5y	1.62
ROCE	6.79
ROE	17.13
Roe5y	6.1
ROIC	11.97
Roic5y	1.82

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	11.16%
Cagr15y	25.8%
Cagr1y	109.74%
Cagr20y	9.92%
Cagr3y	40.78%
Cagr5y	21.31%
EPS Growth Quarters	4
EPS Growth Years	1
EPS Growth3 Y	74.89
EPS Growth5 Y	25.56
FCF Growth	141.52%
FCF Growth3 Y	5.65%
FCF Growth5 Y	24.85%
OCF Growth	133.58%
OCF Growth10 Y	10.08%
OCF Growth3 Y	1.02%
OCF Growth5 Y	20.59%
Revenue Growth	51.24x
Revenue Growth Q	14.09x
Revenue Growth Quarters	8x
Revenue Growth Years	2x
Revenue Growth3 Y	10.45x
Revenue Growth5 Y	5.66x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.23
Assets	$1.5B
Cash	$779.4M
Current Assets	$865.4M
Current Liabilities	$40.7M
Debt	$452M
Debt EBITDA	$3.34
Debt Equity	$0.45
Debt FCF	$3.67
Equity	$997.3M
Interest Coverage	18.09
Liabilities	$534.8M
Long Term Assets	$666.7M
Long Term Liabilities	$494.1M
Net Cash	$327.4M
Net Cash By Market Cap	$7.38
Net Cash Growth	60.15%
Net Debt EBITDA	$-2.44
Net Debt Equity	$-0.33
Net Debt FCF	$-2.66
Tangible Book Value	$678.4M
Tangible Book Value Per Share	$33.87
WACC	9.3

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	21.28
Inventory Turnover	3.32
Net Working Capital	$46.4M
Quick ratio	20.81
Working Capital	$824.7M
Working Capital Turnover	$0.51

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-9.72%
Dividend per share	$0
Dividend Yield	0%
Last Dividend	$15

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	187.93%
1Y total return	109.63%
200-day SMA	189.3
3Y total return	179.1%
50-day SMA	214
50-day SMA vs 200-day SMA	50over200
5Y total return	162.69%
All Time High	278.6
All Time High Change	-20.53%
All Time High Date	2018-10-01
All Time Low	6.6
All Time Low Change	3,254.7%
All Time Low Date	2008-10-28
ATR	11.44
Beta	1.07
Beta1y	0.69
Beta2y	0.92
Ch YTD	17.11
High	223.8
High52	247.4
High52 Date	2026-04-27
High52ch	-10.5%
Low	206
Low52	98.89
Low52 Date	2025-05-30
Low52ch	123.9%
Ma50ch	3.48%
Price vs 200-day SMA	16.99%
RSI	49.87
RSI Monthly	73.56
RSI Weekly	62.63
Sharpe ratio	2.11x
Sortino ratio	3.51
Total Return	-9.72%
Tr YTD	17.11
Tr15y	3,027.8%
Tr1m	7.95%
Tr1w	-2.65%
Tr3m	16.26%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	3
Analyst Price Target Top	$250
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$1.64
Earnings EPS Estimate Growth	23.31
Earnings Revenue Estimate	59,056,624x
Earnings Revenue Estimate Growth	30.27x
Operating Income	$101.2M
Operating Income Growth3 Y	88.52
Operating Income Growth5 Y	27.23
Operating margin	36.88
Price target	$258
Price Target Change	$16.4
Price Target Change Top	$13.06

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	19,564,191%
Float Percent	97.62%
Net Borrowing	346,723,000
Shares Insiders	2.34%
Shares Institutions	105.15%
Shares Out	20,041,061
Shares Qo Q	-5.94%
Shares Yo Y	9.72%
Short Float	7.19%
Short Ratio	5.62
Short Shares	7.02

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$73.4M
Average Volume	235,541.6x
Bv Per Share	49.79
CAPEX	$-466,000
Ch10y	85.79
Ch15y	1,918.3
Ch1m	7.95
Ch1w	-2.65
Ch1y	109.6
Ch20y	220.9
Ch3m	16.26
Ch3y	179.1
Ch5y	69.51
Ch6m	9.35
Change	5.27%
Change From Open	4.34
Close	210.3
Days Gap	0.89
Depreciation Amortization	33,221,000
Dollar Volume	55,344,972.1
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$101.2M
EBITDA	$134.4M
EPS	$7.5
F Score	6
FCF	$123M
FCF EV Yield	2.99x
FCF Per Share	$6.14
Financing CF	418,837,000
Fiscal Year End	December
Founded	1,987
Goodwill	101,541,000
Graham Number	91.66343
Graham Upside	-58.6
Income Tax	$31.3M
Investing CF	-476,563,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Date	2010-11-19
Last Split Type	Reverse
Last10k Filing Date	2026-02-27
Lynch Fair Value	$187
Lynch Upside	-15.32
Ma150	199.9
Ma150ch	10.76%
Ma20	227.6
Ma20ch	-2.72%
Net CF	67,105,000
Next Earnings Date	2026-08-06
Open	212.2
Optionable	Yes
P FCF Ratio	36.07
P OCF Ratio	35.93
Position In Range	86.61
Post Close	221.4
Postmarket Change Percent	1.11
Postmarket Price	$224
Ppne	10,278,000
Price Date	2026-05-08
Price EBITDA	$33
Ptbv Ratio	6.54
Relative Volume	1.06x
Revenue	274,476,000x
SBC By Revenue	18.07x
Share Based Comp	49,609,000
Tax By Revenue	11.41x
Tax Rate	16.94%
Tr20y	563.23%
Tr6m	9.35%
Us State	Florida
Volume	249,966
Z Score	5.13

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LGND pay a dividend?

Capital-return profile for this ticker.

Performance

LGND stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LGND?

Insider, institutional, and short-interest positioning.

Institutional ownership

+105.2%

Float: +97.6% of shares outstanding

Insider ownership

+2.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LGND momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

49.9

Neutral momentum band

Price vs 200-day MA

+17.0%

50/200-day relationship not available

Beta (5Y)

1.07

Moves roughly with the market

Sharpe ratio

2.11

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LGND

Hub-level FAQ points readers to the deeper analysis pages.

What is the current LGND stock rating?

Ligand Pharmaceuticals Incorporated is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full LGND analysis?

The full report lives at /stocks/LGND/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for LGND?

The latest report frames LGND around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the LGND page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.